Tianeptine Is Leaving Gas Stations. Withdrawal Is Still Here.

I keep coming back to one object: a red plastic bottle of ZaZa Red with a black screw cap and the words “dietary supplement” on its label. Before anyone opens it, the bottle explains much of the tianeptine problem. It looks ordinary enough to sit near energy shots, nicotine products and over-the-counter remedies for sleep or focus. Nothing about its placement suggests a pharmacy counter, a medication guide or a clinician checking what else a customer takes.

That placement was the business model.

Tianeptine is used as an antidepressant in some countries, but the Food and Drug Administration has never approved it for any use in the United States. Companies here have sold products containing it as supplements, research chemicals or mood enhancers, even though the FDA does not consider tianeptine a lawful dietary ingredient. The drug acts in part as an agonist at the mu-opioid receptor, meaning it activates a receptor involved in opioid effects, physical dependence and suppressed breathing.

The shelf blurred all of that. A supplement-style bottle looked close enough to the magnesium capsules a few hooks away, while the store completed an ordinary retail transaction and the customer took home most of the uncertainty about the dose, the ingredients, possible interactions and what stopping might feel like.

That arrangement is under pressure now. More states have banned or scheduled tianeptine, making its retail sale illegal in parts of the country, while federal regulators have pursued sellers through import controls, warning letters, product seizures and enforcement against unapproved drugs. The red bottle may vanish from a counter. An empty hook can resemble a solved problem.

For a person whose body has adapted to tianeptine, it is the start of another one.

The shelf was a regulatory loophole with good lighting

Federal law does not allow a company to turn any chemical into a dietary supplement by putting those words on the label. The ingredient must fit categories established by statute, and a product marketed as a treatment for disease can come under drug rules regardless of the font or bottle color. Tianeptine products have collided with both limits. The FDA does not accept the ingredient as lawful for supplements, while sellers have promoted products in ways that suggest relief from anxiety, pain, depression or opioid withdrawal.

Enforcement rarely works like a light switch. The FDA can warn a company, block certain imports, seek a seizure or coordinate a recall, but the products pass through manufacturers, importers and distributors before reaching online storefronts or independent retailers. Action against one brand does not remove tianeptine from every package sold under a different name. Detaining imports can tighten supply without stopping bottles already circulating inside the country.

A recall reaches only the products that sellers and customers can identify, and only if the notice reaches them.

State controls produce a second, uneven map. Some states place tianeptine in a controlled-substance schedule, which subjects possession and sale to drug law. Others bar retail sales through legislation or administrative action. The same red bottle can therefore have a different legal status across a state line, while online vendors probe the gaps among shipping rules, payment systems and local enforcement.

The patchwork still has value. Fewer open shelves mean fewer people meet tianeptine as though it were a routine wellness product, and retail bans deny manufacturers some of the borrowed credibility that comes from a familiar convenience-store counter. The transaction had looked banal. That was part of the danger.

The mistake is treating reduced availability as completed care. A ban changes supply. Dependence remains in the nervous system.

Dependence does not obey the recall notice

Physical dependence means the body has adapted to repeated exposure and reacts when the drug is reduced or stopped. It is different from addiction, which includes compulsive use despite harm, though one person can experience both. Neither term measures character.

Case reports, poison-center data and federal health warnings describe tianeptine withdrawal that can resemble opioid withdrawal. People may experience intense agitation and gastrointestinal distress, with sweating, pain, insomnia or a racing heart adding to the strain. Some reported cases have required hospital care, particularly when other substances were involved or no one could be sure what the product contained. Researchers have less evidence for tianeptine than for heroin, fentanyl or prescription opioids.

That uncertainty gives clinicians more to judge, not less.

A person may have started with a bottle like ZaZa Red because it sat openly on a store shelf and did not resemble an illicit drug. Another may have been trying to manage pain or depression, or to avoid withdrawal from a different opioid. Public reporting does not establish how often each path occurs, and I do not want to flatten them into one story. The shared condition is a market that offered drug-level risk without the manufacturing standards and clinical oversight expected of an approved drug.

When local sales stop, a regular customer may face an abrupt interruption. Some people may search online, try an unfamiliar substitute or enter an illicit opioid supply that carries greater risk. That is not an argument for leaving ZaZa Red beside the energy shots. It is an argument for building an off-ramp before removing the product from people whose bodies already expect it.

The red bottle disappears faster than tolerance. Tolerance is the reduced response that develops after repeated exposure, and it can fall during a period without opioids. If someone later returns to the amount previously used, that amount may now cause an overdose. Mislabeled or counterfeit products make the calculation worse because the buyer may not know the active drug, its concentration or whether the bottle contains another depressant.

Withdrawal care cannot be improvised at the register

No medication carries FDA approval specifically for tianeptine withdrawal. That does not mean clinicians have no way to respond. Published cases describe monitoring and treatment of individual symptoms, while some patients have received medications already used for opioid use disorder, including buprenorphine. The literature consists largely of case reports and small clinical studies rather than large trials designed around tianeptine, so clinicians must account for the person’s pattern of exposure, current symptoms, medical conditions and use of other drugs.

Buprenorphine is a partial opioid agonist, meaning it activates opioid receptors enough to reduce withdrawal and craving while placing a ceiling on some opioid effects. If started at the wrong time, it can precipitate withdrawal by displacing another opioid from receptors and rapidly worsening symptoms. An online schedule cannot replace an assessment. This article does not provide dosing instructions.

Emergency departments can evaluate severe withdrawal, dehydration, confusion, chest symptoms or exposure to unknown ingredients. Addiction-medicine clinicians and opioid treatment programs can consider whether continuing medication treatment is appropriate, rather than framing the encounter as a brief detox that ends once the immediate symptoms ease. The Substance Abuse and Mental Health Services Administration maintains a treatment locator. In the United States, poison control centers can also respond to suspected poisoning or withdrawal.

Overdose is a separate emergency. If someone cannot be awakened, has slowed or stopped breathing, or has blue or gray lips, call 911. Naloxone can reverse opioid-related respiratory depression and may be used when opioid exposure is suspected, even if the exact contents of a product are unknown. Emergency evaluation remains necessary because a tianeptine product may contain other substances and symptoms may return.

Care also means asking what work the bottle had been doing. Removing a product that suppressed untreated pain, anxiety or depression leaves the underlying condition in place. If someone used tianeptine to avoid withdrawal from fentanyl or another opioid, punishment adds risk while evidence-based opioid treatment remains relevant. A clinician does not have to approve of the choice to understand the mechanism behind it.

This is not personal medical advice. It is the basic structure of a serious public response: recognize opioid-like dependence, assess the person without shaming them and connect an acute episode to continuing care. Confiscating the bottle does none of those things.

The people who sold normality keep their distance

The tianeptine market turned regulatory ambiguity into retail trust. Manufacturers and distributors put a potent psychoactive ingredient inside the familiar visual language of supplements, then stores supplied the credibility of a counter where people also bought drinks and ordinary remedies. Customers paid for the red bottle. Public systems later handled poison calls and emergency visits, along with the slower work of treatment after a seller had moved the inventory.

State bans can interrupt that system, especially for people who have never heard of tianeptine and encounter it casually. Federal action against unlawful imports and marketing can raise the cost of distribution and make the products less visible. Those gains are real. Criminal penalties directed at individual users are harder to defend when fear of punishment may keep someone from bringing a package to an emergency department or naming the substance during a clinical assessment.

Removal should come with notice. Before a prohibition takes effect, retailers and health departments can warn that regular use may lead to withdrawal, while health systems prepare clinicians and make addiction treatment easier to reach. Public messaging should not force every customer into the role of reckless consumer or criminal. Regulators also need to pursue the companies that chose the supplement label and moved the inventory rather than allowing enforcement to stop with the person holding one bottle.

The last image should not be an empty hook where ZaZa Red once hung. The same counter could carry naloxone beside a plain treatment-locator card, with a warning that stopping after regular use may require medical help. The red bottle used shelf space to create an illusion of safety. The correction belongs there too.

Questions people ask

Is tianeptine legal in the United States?

Tianeptine is not FDA-approved for medical use and cannot lawfully be sold as a dietary supplement. State law varies. Several states prohibit or schedule it, while federal agencies can act against unlawful products through import controls, warning letters, recalls and seizures.

Can tianeptine withdrawal be dangerous?

Withdrawal can bring severe agitation and gastrointestinal illness, as well as sweating, pain, insomnia or cardiovascular symptoms. Some reported cases have required hospital care. The risk depends on the person’s exposure, health and use of other substances, so abrupt withdrawal after regular use may warrant medical assessment rather than a plan assembled from social media posts.

How is tianeptine dependence treated?

There is no medication approved specifically for tianeptine withdrawal. Clinicians can monitor for complications, treat symptoms and assess whether established medications for opioid use disorder fit the case. Published reports include treatment with buprenorphine, but its timing and dose require professional evaluation because starting it incorrectly can worsen withdrawal.

Does banning gas-station sales solve the problem?

A ban can reduce casual exposure and strip away some of the false legitimacy created by supplement-style retail. It does not treat anyone already dependent. Without reachable care, some people may turn to online sellers, unknown substitutes or the illicit opioid market. The hook can be empty while the person who bought the red bottle last week is still sick.